Michael Comeau

Michael Comeau has worked in the scientific field for over 30 years. Michael began their career in 1989 as a Research Assistant - Associate Staff Scientist at Immunex. In 2001, they joined Amgen, Inc. as a Scientist and progressed to a Senior Scientist and then a Principal Scientist. In 2015, they moved to Aptevo Therapeutics Inc as a Principal Scientist- Immunobiology. In 2019, they joined Silverback Therapeutics as Director of Biology and Principal Scientist. Most recently, in 2023, they became a Senior Scientific Affairs Liaison at Ozette Technologies. During their time at Amgen, they initiated and led the project team in the successful development of AMG 157, a fully human antibody capable of inhibiting TSLP activity. This multi-year effort required cross-site and departmental team work leading to robust human clinical data published in the New England Journal of Medicine in 2014 and is currently being tested in a global phase 2 human asthma trial.

Michael Comeau received their B.S. in Microbiology/Molecular Biology from Washington State University between 1986 and 1989. Michael is currently enrolled at the University of Alaska, majoring in Biology.